Ticker: NYSE:CNC
Price: $36.40
Change: -$6.92
% Change: -15.974%

Shares of Centene Corporation (NYSE:CNC) were hammered as investors reacted to renewed concern over the ACA marketplace business. MarketWatch reported that Centene now expects a roughly 40% decline in ACA marketplace enrollment by year-end, with enrollment already down from 5.5 million in December to 3.5 million by the end of the first quarter. Barron’s added that the market was disappointed that management merely reaffirmed guidance instead of offering upside, while uncertainty around Medicare rates also remained in the background.

Company Overview

Centene is one of the largest managed-care organizations in the U.S., with operations across Medicaid, Medicare, and the ACA marketplace. The company’s strategy has long centered on government-sponsored healthcare, particularly serving complex and lower-income populations across multiple states. That makes it both deeply relevant to public-policy trends and highly sensitive to rate setting, medical cost inflation, and enrollment shifts.

The market’s concern here is straightforward: when one of Centene’s most important engines, the ACA marketplace, sees a rapid member decline or worsening morbidity, the earnings model becomes harder to underwrite.

Financial Performance

Centene’s last full-year results were mixed. For 2025, the company reported total revenue of $194.8 billion and premium and service revenue of $174.6 billion. Full-year adjusted diluted EPS was $2.08, while GAAP diluted loss per share was $(13.53) due largely to goodwill impairment and other charges. Operating cash flow for the year came in at $5.09 billion.

In the fourth quarter, total revenue was $49.7 billion, and the consolidated health benefits ratio was 94.3%, including a Commercial HBR of 95.4%. That HBR was above expectations, reflecting marketplace morbidity and other pressures. Medicaid showed some progress sequentially, but the marketplace and PDP businesses continued to shape the debate around earnings quality.

Reason Behind the Selloff

Today’s decline looks tied less to the headline 2025 numbers and more to what management said about 2026 marketplace dynamics. The most important issue is that Centene appears to be prioritizing margin over membership growth in ACA exchange products. Barron’s reported that the company is willing to accept lower membership as part of a pricing strategy designed to improve profitability. The problem for the stock is that a 40% membership decline is a large number, and investors worry about what that implies for revenue mix, scale, and near-term visibility.

This is a classic “show me” setup. Reaffirming EPS guidance is not always enough when the market sees a sharp enrollment contraction and still has unanswered questions on Medicare Advantage margins and final CMS rates.

Management Outlook and Guidance

Management’s official guidance remains constructive. In its February results release, Centene said it expects 2026 adjusted diluted EPS greater than $3.00 and GAAP diluted EPS greater than $1.98, with 2026 revenue guidance of $186.5 billion to $190.5 billion. CEO Sarah London said the company had taken “extensive and decisive actions” in the back half of 2025 and was positioned to deliver meaningful margin improvement and renewed adjusted diluted EPS growth in 2026.

That is the bull case: lower marketplace enrollment is painful, but if pricing and underwriting improve enough, margins may recover and earnings may still grow. The bear case is that volatility in membership, morbidity, and rate updates will keep investors skeptical until there is cleaner evidence of stabilization.

Technical Insights

A move to $36.40 is a major technical deterioration for Centene. The stock has now pushed well below the low-$40s zone where many investors were likely watching for support, and today’s decline marks one of its sharpest single-day pullbacks in recent memory. Barron’s called it the worst performer in the S&P 500 on the day.

Key levels to watch:

Support: $35 / $32
Resistance: $40 / $44

If the shares fail to hold the mid-$30s, the market may start pricing in a longer recovery cycle. Any durable rebound likely requires confidence that marketplace attrition is largely planned and that margin recovery is on schedule.

Conclusion

The selloff in Centene Corporation (NYSE: CNC) reflects a credibility gap, not just an earnings issue. Management is still guiding to more than $3.00 in adjusted EPS for 2026 and says the business is positioned for meaningful margin improvement, but investors are focused on the steep projected decline in ACA marketplace enrollment and the uncertainty that creates around the path forward.

Centene remains a massive franchise in government-sponsored healthcare, and if it can successfully trade lower volume for better economics, the stock could eventually recover. For now, though, the market wants proof. Until there is clearer evidence that margins are improving without further erosion in core operating trends, NYSE:CNC may continue to trade as a policy- and execution-sensitive turnaround story.